# UCSF

**UC San Francisco Previously Published Works** 

## Title

MP28-03 PERCEPTIONS OF OLDER MEN USING A MOBILE HEALTH APPLICATION TO MONITOR LOWER URINARY TRACT SYMPTOMS AND TAMSULOSIN ADVERSE EFFECTS: MIXED-METHODS STUDY

#### Permalink

https://escholarship.org/uc/item/4w1866ft

### Journal

Journal of Urology, 206(Supplement 3)

### ISSN

0021-0005

### Authors

Wang, Elizabeth Y Breyer, Benjamin N Lee, Austin <u>et al.</u>

### **Publication Date**

2021-09-01

### DOI

10.1097/ju.0000000000002025.03

### **Copyright Information**

This work is made available under the terms of a Creative Commons Attribution License, available at <u>https://creativecommons.org/licenses/by/4.0/</u>

Peer reviewed

			Upper East Si	de		
	Chain (CP) - Median (IQR)		Independent (IP) - Median (IQR)		Online (OP) - Median (IQR)	ANOVA p-yatra
PDES					( and )	
Tadalafi (5mg qD)	\$264.59 (261.99, 264.59)		\$62.50 (44.25, 86.24)		\$36.30 (32.70, 54.71)	<0.01
5-ARi	847.00	74 50 87 001				
Finasteride (5mg) Dutasteride (0.5mg)	\$87.99 (74.59, 87.99) \$181.99 (165.99, 181.99)		\$30 (15.71, 50.88) \$30 (22.50, 59.25)		\$13.95 (8.25, 21.08) \$22.05 (15.21, 26.55)	<0.01
Alpha Blocker					942.00 (10.2.1, 20.00)	-0.01
Tamsulosin (0.4mg)	\$88.49 (87.99, 88.49)		\$30 (15, 40)		\$14.88 (7.29, 18.83)	<0.01
Doxazosin (8mg)	\$26.99 (18.99, 26.99) \$42.39 (37.59, 42.39)		\$30 (19,48, 51)		\$15.30 (10.35, 20.55)	0.04
Alfuzosin (10mg) Silodosin (8mg)	\$42.39	(37.59, 42.39)	\$37 (18.47, 72.50) \$65 (45, 120)		\$12.90 (7.65, 24.23) \$32 (29.10, 63)	0.06
Terazosin (10mg)	\$188.49 (186.99, 188.49) \$21.99 (19.19, 21.99)		\$30 (19.99, 48.06)		\$12.15 (7.20, 19.20)	<0.01
Antispaismodic		(10.10, 61.00)			\$12.10 (1.20, 10.20)	
Oxybutynin IR (5 mg TID)	\$45.59	(45.59, 57.59)	\$53.50	(28.75, 94.94)	\$36.15 (23.64, 55.65)	0.14
Oxybutynin ER (5 mg qD)		(98.59, 120.99)	\$50 (32.50, 94)		\$16.50 (14.25, 26.78)	<0.01
Mirabegron (25mg)	\$519.99 (487.99, 519.99) \$219.99 (197.99, 219.99)		\$482.50 (446.21, 491.25) \$70 (55, 112.50)		\$441.90 (435.90, 453.60)	<0.01
Tollerodine ER (4mg)	CP vs IP p-		CP vs OP p-	Easter Difference	\$62.85 (58.20, 74.48)	<0.01 Factor Difference
	value [b]	Factor Difference (CPIIP) [c]	value [b]	Factor Difference (CP/OP) [c]	IP vs OP p-value [b]	(IP)OP) [c]
PDE5i Tadalafii (5mg qD)	<0.01	4.23	<0.01	7.29	0.38	1.72
S-ARi	-92,01	4.2.5	-0.01	7.49	0.30	Lira
Finasteride (5mg)	<0.01	2.93	<0.01	6.31	0.04	2.15
Dutasteride (0.5mg)	<0.01	6.07	<0.01	8.25	0.16	1.36
Alpha Blocker	2004	a same b	in conse		200101	S
Tamsulosin (0.4mg)	<0.01	2.95	<0.01	5.95	0.11	2.02
Doxazosin (8mg) Alfuzosin (10mg)	0.06	0.90	0.01	1.76	0.11	2.87
Silodosin (8mg)	<0.01	2.90	<0.01	5.89	0.07	2.03
Terazosin (10mg)	<0.01	0.73	0.02	1.81	0.01	2.47
Antispasmodic						0
Oxybutynin IR (5 mg TID)	0.10	0.85	0.11	1.26	0.27	1,48
Oxybutynin ER (5 mg qD)	0.09 <0.01	2.42	<0.01 <0.01	7.33	0.14	3.03
Mirabegron (25mg) Toterodine ER (4mg)	<0.01	1.08	<0.01	1.18	0.16	1.09
TOREGOINE EX (HILL)	-0.01	0.14	East Harlem	3.00	0.27	1.11
	Chain (CP	) - Median (IQR)	Independent (IP) - Median (IQR)		Online (OP) - Median (IQR)	ANOVA p-value
PDES						2
Tadalafil (5mg qD)	\$264.59 (	263.94, 319.99)	\$40 (22, 60)		\$36.30 (32.70, 54.71)	<0.01
5-ARi			1			9
Finasteride (5mg)	\$87.99 (84.64, 99.99) \$177.50 (171.25, 181.99)		\$15 (10, 20) \$20 (15, 25)		\$13.95 (8.25, 21.08)	<0.01
Dutasteride (0.5mg) Npha Blocker	\$177.501	171.20, 101.99)	82	7(10, 20)	\$22.05 (15.21, 26.55)	40.01
Tamsulosin (0.4mg)	\$88.49	(88.37, 103)	\$15	5 (10, 20)	\$14.88 (7.29, 18.83)	<0.01
Doxazosin (8mg)	\$26.99 (24.99, 47)		\$20 (14.50, 30)		\$15.30 (10.35, 20.55)	0.02
Alfuzosin (10mg)	\$42.39 (41.19, 110)		\$20 (15, 25)		\$12.90 (7.65, 24.23)	<0.01
Silodosin (8mg)	\$188.49 (188.12, 230) \$21.99 (21.29, 46)		\$36 (25.50, 45)		\$32 (29.10, 63)	<0.01
Terazosin (10mg)	\$21.9	3 (21.29, 46)	\$21	0 (15, 25)	\$12.15 (7.20, 19.20)	0.02
Antispasmodic Oxybutynin IR (5 mg TID)	\$51.5	9 (45.59, 72)	\$30	0 (25, 40)	\$36.15 (23.64, 55.65)	0.01
Oxybutynin ER (5 mg qD)	\$115.50 (107.15, 120.99)		\$25 (20, 30)		\$16.50 (14.25, 26.78)	<0.01
Mirabegron (25mg)	\$519.99 (511.99, 535)		\$422.50 (400, 450)		\$441.90 (435.90, 453.60)	<0.01
Toterodine ER (4mg)		(214.49, 247)		37.50, 60)	\$62.85 (58.20, 74.48)	<0.01
	CP vs IP p- value [b]	Factor Difference (CP/IP) [c]	CP vs OP p- value [b]	Factor Difference (CP/OP) [c]	IP vs OP p-value [b]	Factor Different (IP/OP) [c]
PDESI						-
Tadalafii (5mg qD) 5-ARi	<0.01	6.61	<0.01	7.29	0.74	1.10
Finasteride (5mg)	<0.01	5.87	<0.01	6.31	0.58	1.08
				8.05	0.80	0.91
Dutasteride (0.5mg)	<0.01	8.87	<0.01			
Dutasteride (0.5mg) Npha Blocker	1000	S	1.0			a water
Dutasteride (0.5mg) Npha Blocker Tamsulosin (0.4mg)	<0.01	5.90	<0.01	5.95	0.62	1.01
Dutasteride (0.5mg) Npha Blocker Tamsulosin (0.4mg) Doxazosin (8mg)	<0.01 0.02	5.90 1.35	<0.01 0.02	1.76	0.62 0.28	1.31
Dutasteride (0.5mg) Alpha Blocker Tamsulosin (0.4mg) Doxazosin (8mg) Alfuzosin (10mg)	<0.01 0.02 <0.01	5.90 1.35 2.12	<0.01 0.02 0.01	1.76 3.29	0.62 0.28 0.46	1.31
Dutasteride (0.5mg) Alpha Blocker Tamsulosin (0.4mg) Doxazosin (8mg) Alfuzosin (10mg) Silodosin (8mg)	<0.01 0.02	5.90 1.35	<0.01 0.02	1.76	0.62 0.28	1.31
Dutasteride (0.5mg) Npha Blocker Tamsulosin (0.4mg) Doxazosin (8mg) Afluzosin (10mg) Silodosin (8mg) Terazosin (10mg) Artispasmodic	<0.01 0.02 <0.01 <0.01 0.03	5.90 1.35 2.12 5.24 1.10	<0.01 0.02 0.01 <0.01 0.04	1.76 3.29 5.89 1.81	0.62 0.28 0.46 0.98	1.31 1.55 1.13 1.65
Dutasteride (0.5mg) Apha Blocker Tamsulosin (0.4mg) Doxazosin (6mg) Alfuzosin (10mg) Silodosin (8mg) Terazosin (10mg) Artispasmodic Oxybutynin IR (5 mg TID)	<0.01 0.02 <0.01 <0.01 0.03 <0.01	5.90 1.35 2.12 5.24 1.10 1.72	<0.01 0.02 0.01 <0.01 0.04 0.24	1.76 3.29 5.89 1.81	0.62 0.28 0.46 0.98 0.10 0.28	1.31 1.55 1.13 1.65 0.83
Dutasteride (0.5mg) Npha Blocker Tamsukosin (0.4mg) Doxazosin (10mg) Attuzosin (10mg) Sidodasin (40mg) Terazosin (10mg) Artispasmodic Oxybutynin IR (5 mg TID) Oxybutynin IR (5 mg TID)	<0.01 0.02 <0.01 <0.03 <0.01 0.03 <0.01 <0.01	5.90 1.35 2.12 5.24 1.10 1.72 4.62	<0.01 0.02 0.01 <0.01 0.04 0.24 <0.01	1.76 3.29 5.89 1.81 1.43 7.00	0.62 0.28 0.46 0.18 0.10 0.28 0.34	1.31 1.55 1.13 1.65 0.83 1.52
Dutasteride (0.5mg) Apha Blocker Tamsukosi (0.4mg) Doxazosin (8mg) Afluzosin (10mg) Silodosin (8mg) Terazosin (10mg) Writispasmodic Oxybulynini R (5 mg QD) Mrabegron (25mg)	<0.01 0.02 <0.01 <0.03 <0.01 <0.01 <0.01 <0.01 <0.01	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23	<0.01 0.02 0.01 <0.01 0.04 0.24 <0.01 <0.01	1.76 3.29 5.89 1.81 1.43 7.00 1.18	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47	1.31 1.55 1.13 1.65 0.83 1.52 0.96
Dutasteride (0.5mg) Npha Blocker Tamsukosin (0.4mg) Doxazosin (10mg) Attuzosin (10mg) Sidodasin (40mg) Terazosin (10mg) Artispasmodic Oxybutynin IR (5 mg TID) Oxybutynin IR (5 mg TID)	<0.01 0.02 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 billy in Indece	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.89 ndent Pharmacy Ere	<0.01 0.02 0.01 0.04 0.24 <0.01 <0.01 <0.01	1.76 3.29 5.89 1.81 1.43 7.00 1.18 3.50	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.45	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72
Dutasteride (0.5mg) Vipha Blocker Tamsulosin (0.4mg) Doxazosin (8mg) Afluzosin (10mg) Sidodain (8mg) Terazosin (10mg) Velspaarmodic Oxybutynin (R (5 mg TID) Oxybutynin (R (5 mg TID) Mirabegron (25mg) Toterodine ER (4mg)	<0.01 0.02 <0.01 <0.01 0.03 <0.01 <0.01 <0.01 <0.01 bility in Indepen Upper East S	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.89 ndent Pharmacy Ere do (UES) - Median	<0.01 0.02 0.01 0.04 0.24 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01	1.76 3.29 5.89 1.81 1.43 7.00 1.18 3.50	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.45 p Based on Neighborhood	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72 Factor Difference
Dutasteride (0.5mg) lyha Blocker Tamukosh (0.4mg) Doxasosh (10mg) Aluzosh (10mg) Velapasmode Ozykołynin IR (5mg (10) Ozykołynin IR (5mg (10) Ozykołynin IR (5mg (10) Ozykołynin ER (5mg (10) Toterodine ER (4mg) 1b. Varia	<0.01 0.02 <0.01 <0.01 0.03 <0.01 <0.01 <0.01 <0.01 bility in Indepen Upper East S	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.89 ndent Pharmacy Ere	<0.01 0.02 0.01 0.04 0.24 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01	1.76 3.29 5.89 1.81 1.43 7.00 1.18 3.50 m Medication Pricit	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.45	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72
Dutasteride (0.5mg) ghata Blocker Tamautosin (0.4mg) Doxazosin (8mg) Altuzosin (10mg) Sibdosin (8mg) Terrazosin (10mg) Ireitapasmodic Oxybudynin ER (5 mg (10) Oxybudynin ER (5 mg (10) Toterodine ER (5 mg (20) Mrabegron (25mg) Toterodine ER (4mg) 1b. Varia PDE5	<0.01 0.02 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 billty in Indeper Upper East S	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.89 ndent Pharmacy Ere do (UES) - Median	<0.01 0.02 0.01 <0.01 0.04 0.24 <0.01 <0.01 <0.01 ctile Dysfunctie East Hartern (	1.76 3.29 5.89 1.81 1.43 7.00 1.18 3.50 m Medication Pricit	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.45 p Based on Neighborhood	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72 Factor Difference
Dutasteride (0.5 mg) kyha Blocker Tamukosin (0.4 mg) Doxacosin (6mg) Altuzosin (10 mg) Stodosin (10 mg) Terazosin (10 mg) Verlapasmodic Oxytotymin ER (5 mg 10) Mrabegon (25 mg) Toterodine ER (4 mg) 1b. Varia PDE5 Tadialfa (5 mg 0) SARI	<0.01 0.02 0.01 0.03 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 bility in Indepe Upper East S \$62.50	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.89 def (Pharmacy Ere def (UEB) - Median (UCR) (44.25, 86.24)	<0.01 0.02 0.01 <0.01 0.04 0.24 <0.01 <0.01 <0.01 ctile Dysfunctis East Harisen ( \$44	1.76 3.29 5.89 1.81 1.43 7.00 1.13 3.50 on Medication Pricin EH) - Median (IQR)	0 62 0 28 0 46 0 98 0 10 0 28 0 34 0 47 0 47 g Based on Neighborhoot p-value [b] 0.33	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72 Factor Differen (UES/EH) [c] 1.58
Dutasteride (0.5mg) Upta Blocker Tamutosin (0.4mg) Doxacasin (10mg) Alturosin (10mg) Terazosin (10mg) Terazosin (10mg) Velapatrosic Orysolynin (15 mg 10) Orysolynin (15 mg 10) Orysolynin (15 mg 10) Toterodine ER (4mg) 16. Veria POES Tadalafi (5mg q0) SARI	<ul> <li>&lt;0.01</li> <li>0.02</li> <li>&lt;0.01</li> <li>&lt;</li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 4.69 mdent Pharmacy Ere do (UEB) - Median (UR) (44.25, 66.24) 5.71, 50.80	<0.01 0.02 0.01 <0.01 0.04 0.04 0.04 <0.01 <0.01 <0.01 <0.01 <0.01 Enst Harlern ( \$40 \$10 \$10 \$10 \$10 \$10 \$10 \$10 \$1	1.76 3.29 5.89 1.81 1.43 7.00 1.18 3.50 on Medication Pricin EH) - Median (IQR) 0.02, 60) 5 (10, 20)	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.47 g Based on Heighborhooc p-value [b] 0.33 40.01	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72 Factor Different (UES/EH) [c] 1.56 2.00
Dutasteride (0.5 mg) kyha Blocker Tamukosin (0.4 mg) Doxazoain (mg) Altuzosin (10 mg) Stodosin (10 mg) Terazosin (10 mg) Viritapasmodic Oxytotymin ER (5 mg 10) Mrabegon (25 mg) Toterodine ER (4 mg) Toterodine ER (4 mg) Toterodine (5 mg 0) SAR Finasteride (5 mg) Dutasteride (5 mg)	<ul> <li>&lt;0.01</li> <li>0.02</li> <li>&lt;0.01</li> <li>&lt;</li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.89 def (Pharmacy Ere def (UEB) - Median (UCR) (44.25, 86.24)	<0.01 0.02 0.01 <0.01 0.04 0.04 0.04 <0.01 <0.01 <0.01 <0.01 <0.01 Enst Harlern ( \$40 \$10 \$10 \$10 \$10 \$10 \$10 \$10 \$1	1.76 3.29 5.89 1.81 1.43 7.00 1.13 3.50 on Medication Pricin EH) - Median (IQR)	0 62 0 28 0 46 0 98 0 10 0 28 0 34 0 47 0 47 g Based on Neighborhoot p-value [b] 0.33	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72 Factor Differen (UES/EH) [c] 1.58
Dutasteride (0.5 mg) ghan Blocker Tamuskoin (0.4 mg) Doxazosin (40 mg) Alfuzosin (10 mg) Stodosin (10 mg) Terazosin (10 mg) Matalegran (25 mg) Telescoline ER (5 mg dD) Matalegran (25 mg) Telescoline ER (5 mg dD) Matalegran (25 mg) Telescoline ER (5 mg dD) Tedeladie (10 mg dD) SAR Plasteride (10 mg) Dutasteride (0.5 mg) Dutasteride (0.5 mg) Dutasteride (0.5 mg)	<ul> <li>(0,01)         (0,02)         (0,01)         (0,01)         (0,03)         (0,01)</li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 4.62 4.69 Metan (IGR) (IGR) (42.5, 66.24) 5.71, 50.68) 2.50, 59.25)	<0.01 <0.01 <0.02 <0.01 <0.04 <0.04 <0.04 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0	1.76 3.29 5.89 1.81 1.43 7.00 1.18 3.50 on Medication Prior EH) - Median (IQR) 0 (22, 60) i (10, 20) (15, 25)	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.47 g Based on Heighborhooc p-value [b] 0.33 40.01 0.07	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72 Factor Differens (UESGH) [c] 1.56 2.00 1.50
Dutasteride (0.5 mg) kyha Blocker Tamutosin (0.4 mg) Doxazosin (10 mg) Alturosin (10 mg) Stodosin (10 mg) Terazosin (10 mg) Viritigasemodic Oxytotynin ER (5 mg 10) Mrabegon (25 mg) Toterosine ER (4 mg) Toterosine ER (4 mg) Toterosine (5 mg) Dutasteride (5 mg)	<ul> <li>&lt;0.01</li> <li>0.02</li> <li>&lt;0.01</li> <li>&lt;</li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.80 (UCR) - Median (UCR) (UCR) (UCR) - Median (UCR) (UCR) - Median (UCR) 5.71, 50.80 2.50, 59.25) (15, 40)	<ul> <li>&lt;0.01</li> <li>0.02</li> <li>0.01</li> <li>&lt;0.01</li> <li>&lt;0.04</li> <li>&lt;0.04</li> <li>&lt;0.04</li> <li>&lt;0.01</li> <li>&lt;0</li></ul>	1,76 3,29 5,89 1,81 1,43 7,00 1,18 3,50 50 MdCation Pricin EH) - Median (IQR) 9 (22,60) 0 (21,00) (15,25) 5 (10,20)	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.47 0.47 0.47 0.47 0.33 0.33 	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72 Factor Differen- (UES/EH) [c] 1.56 2.00 1.50 2.00
Dutasteride (0.5 mg) ghan Blocker Tamuskoin (0.4 mg) Doxazosin (10 mg) Alfuzosin (10 mg) Stodosin (10 mg) Terazosin (10 mg) Matalegran (25 mg) Terazosin (16 mg) Matalegran (25 mg) Toterodine B( mg) Distanting (10 mg)	<ul> <li>&lt;0.01</li> <li>&lt;0.02</li> <li>&lt;0.01</li> <li></li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.69 dear (Pharmacy Ere loc (UES) - Median (UR) (44.25, 66.24) 5.71, 50.88) 2.40, 59.25) (15.40) (19.46, 51)	<ul> <li>&lt;0.01</li> <li>0.02</li> <li>0.01</li> <li>&lt;0.01</li> <li>&lt;0</li></ul>	1,76 3,29 5,89 1,81 1,81 1,43 7,00 1,18 3,50 0,00 (1,1,00 0,00 0,00 0,00 0,00 0,00	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.4	1.31 1.55 1.13 1.65 0.83 0.83 0.96 0.72 0.96 Fector Different (UES/EH) [c] 1.56 2.00 1.50
Dutasteride (0.5 mg) ghan Blocker Ternutoxin (0.4 mg) Doxazosin (10mg) Alfuzosin (10mg) Stodoxin (10mg) Stodoxin (10mg) Veriapasmodie Oxytodynin BR (5 mg, 10) Oxytodynin BR (5 mg, 10) Mrabegron (25mg) Toterodine BR (4 mg) Toterodine BR (4 mg) Doxet (10mg) Dutasteride (0.6 mg) Dutasteride (0.6 mg) Dutasteride (0.6 mg) Doxazosin (10mg) Alfuzosin (10mg) Stodoxin (10mg)	<ul> <li>&lt;0.01</li> <li>&lt;0.02</li> <li>&lt;0.01</li> <li></li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.69 <b>dent Pharmacy Ere</b> (0R) (44.25, 66.24) 5.71, 50.88) 2.50, 59.25) (15.40) (19.45, 51) 8.47, 72.50) (45, 120)	+0.01 •0.01 •0.01 •0.01 •0.01 •0.04 •0.01 •0	1,76 3,29 5,89 1,81 1,43 7,00 1,18 3,50 50 MdCation Pricin EH) - Median (IQR) 9 (22,60) 0 (21,00) (15,25) 5 (10,20)	0.62 0.28 0.46 0.98 0.10 0.28 0.37 0.47 0.47 0.47 0.47 0.47 0.33 0.33 0.33 0.33	1.31 1.55 1.13 1.65 0.83 1.52 0.96 0.72 Factor Differen- (UES/EH) [c] 1.56 2.00 1.50 2.00
Dutasteride (0.5 mg) ghan Blocker Ternutoxin (0.4 mg) Doxazosin (10mg) Alfuzosin (10mg) Stodoxin (10mg) Stodoxin (10mg) Veriapasmodie Oxytodynin BR (5 mg, 10) Oxytodynin BR (5 mg, 10) Mrabegron (25mg) Toterodine BR (4 mg) Toterodine BR (4 mg) Doxet (10mg) Dutasteride (0.6 mg) Dutasteride (0.6 mg) Dutasteride (0.6 mg) Doxazosin (10mg) Alfuzosin (10mg) Stodoxin (10mg)	<ul> <li>&lt;0.01</li> <li>&lt;0.02</li> <li>&lt;0.01</li> <li></li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 4.62 1.23 4.60 (USS) - Median (UR) (UR) (V4.25, 66.24) 5.77, 50.68) 2.60, 59.25 (15, 40) 19.46, 51) 8.47, 72.50)	<0.01 <0.01 <0.01 <0.01 <0.04 <0.04 <0.04 <0.04 <0.01 <0.01 <0.01 East Harten ( \$44 \$44 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$57 \$56 <	1,76 3,29 5,89 1,81 1,43 7,00 1,18 3,50 0,00 0,00 0,00 0,00 0,00 0,00 0,00	0.62 0.28 0.46 0.10 0.28 0.34 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.4	1.31 1.65 1.13 1.65 0.83 1.52 0.96 0.72 Factor Different (UESGH) [c] 1.56 2.00 1.50 2.00 1.50
Dutasteride (0.5 mg) ghan Blocker Tamuskoin (0.4 mg) Doxazosin (10mg) Stobain (10mg) Stobain (10mg) Stobain (10mg) Terazosin (10mg) Marabegron (25mg) Toterodine B( 4 mg) Toterodine B( 4 mg) Toterodine B( 4 mg) Toterodine B( 4 mg) Dutasteride (10mg) Dutasteride (10mg) Dutasteride (10mg) Dutasteride (10mg) Dutasteride (10mg) Alfuzosin (10mg) Terazosin (10mg) Terazosin (10mg)	<ul> <li>-0.01</li> <li>-0.02</li> <li>-0.01</li> <li></li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.69 Medan (UGR) (UGR) (44.25, 66.24) 5.71, 50.88) 2.50, 59.25) (15.40) (15.45, 51) 8.47, 72.50) (45, 120) 9.89, 48.06)	-0.01 0.02 0.01 0.04 0.24 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.04 -0.01 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.04 -0.01 -0.01 -0.04 -0.01 -0.04 -0.01	1,76 3,29 5,89 1,81 1,43 7,00 1,18 3,50 6,00 1,18 3,50 5,00 1,18 5,50 1,100 1,	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.47 0.47 0.47 0.47 0.47 0.53 0.53 0.53 0.07 0.09 0.09 0.09 0.09 0.09 0.00 0.00	1.31 1.55 1.55 1.65 1.52 1.52 0.96 0.72 Factor Differen- (UES/FH) [c] 1.56 2.00 1.50 1.50 1.50 1.50
Dutasteride (0.5mg) kyha Blocker Tamusosin (0.4mg) Doxazosin (10mg) Altuzosin (10mg) Stodosin (10mg) Terazosin (10mg) Kitapasmodic Oxytubynin ER (5mg 0D) Mrabegon (25mg) Toterodine ER (4mg) Toterodine ER (4mg) PDES Todalif (5mg 0D) SARI Finasteride (5mg) Dutasteride (0.5mg) Byha Blocker Tamusolosin (0.4mg) Doxazosin (10mg) Sidodosin (10mg) Sidodosin (10mg)	<ul> <li>-0.01</li> <li>-0.02</li> <li>-0.01</li> <li></li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.62 1.23 4.62 1.24 4.62 1.25 1.62 1.25 1.00 1.72 4.62 1.25 1.00 1.72 4.62 1.25 1.00 1.72 4.62 1.25 1.00 1.72 4.62 1.25 1.00 1.72 4.62 1.25 1.00 1.72 4.62 1.25 1.00 1.72 4.62 1.25 1.00 1.72 4.62 1.25 1.00 1.72 4.62 1.25 1.00 1.72 1.25 1.00 1.72 1.25 1.00 1.72 1.25 1.00 1.72 1.25 1.00 1.72 1.25 1.00 1.72 1.25 1.00 1.72 1.25 1.00 1.25 1	<ul> <li>-0.01</li> <li>-0.01</li> <li>0.02</li> <li>-0.01</li> <li>-0.04</li> <li>-0.04</li> <li>-0.04</li> <li>-0.01</li> <li>-</li></ul>	1.76 3.29 5.89 1.81 1.43 7.00 1.143 7.20 1.145 7.20 1.1	0.62 0.28 0.46 0.10 0.28 0.34 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.4	1.31 1.55 1.55 1.55 1.55 1.55 1.55 1.55
Dutasteride (0.5 mg) Apha Blocker Tamusoin (0.4 mg) Doxazosin (16 mg) Alfuzosin (10 mg) Stolosin (10 mg) Terazosin (10 mg) Verlipastmode Oxytodynin R (5 mg, 10) Oxytodynin R (5 mg, 10) Oxytodynin R (5 mg, 10) Toterodine S (5 mg, 0) Toterodine S (6 mg) Toterodine (16 mg) Dutasteride (16 mg) Dutasteride (16 mg) Dutasteride (16 mg) Dutasteride (16 mg) Dutasteride (16 mg) Alfuzosin (10 mg) Alfuzosin (10 mg)	<ul> <li>-0.01</li> <li>-0.02</li> <li>-0.01</li> <li></li></ul>	5.90 1.35 2.12 5.24 1.10 1.72 4.62 1.23 4.69 Medan (UGR) (UGR) (44.25, 66.24) 5.71, 50.88) 2.50, 59.25) (15.40) (15.45, 51) 8.47, 72.50) (45, 120) 9.89, 48.06)	<ul> <li>-0.01</li> <li>-0.01</li> <li>0.02</li> <li>0.01</li> <li>-0.01</li> <li>0.24</li> <li>-0.01</li> <li>-0</li></ul>	1,76 3,29 5,89 1,81 1,43 7,00 1,18 3,50 6,00 1,18 3,50 5,00 1,18 5,50 1,100 1,	0.62 0.28 0.46 0.98 0.10 0.28 0.34 0.47 0.47 0.47 0.47 0.47 0.47 0.53 0.53 0.53 0.07 0.09 0.09 0.09 0.09 0.09 0.00 0.00	1.31 1.55 1.55 1.65 1.52 1.52 0.96 0.72 Factor Differen- (UES/FH) [c] 1.56 2.00 1.50 1.50 1.50 1.50

[c] p values derived from Mann Whitney O feat with an agina of 0.05 denoting statistically significant deterences [c] Factor difference between median drug pricing (i.e. 4.23 = median price at a chain pharmacy is 4.23 times gre

Source of Funding: None

#### **MP28-03**

#### PERCEPTIONS OF OLDER MEN USING A MOBILE HEALTH APPLICATION TO MONITOR LOWER URINARY TRACT SYMPTOMS AND TAMSULOSIN ADVERSE EFFECTS: MIXED-METHODS STUDY

Elizabeth Y. Wang\*, New York, NY; Benjamin N. Breyer, Austin Lee, Natalie Rios, Akinyemi Oni-Orisan, Michael A. Steinman, Ida Sim, Stacey A. Kenfield, Scott R. Bauer, San Francisco, CA

WITHDRAWN

#### MP28-04 THE 10-ITEM LURN SYMPTOM INDEX DETECTS ADDITIONAL SYMPTOMS AND SHOWS CONVERGENT VALIDITY WITH THE AUA-SI IN MEN WITH BENIGN PROSTATIC HYPERPLASIA

Clark Judge\*, Tanya Kristof, Chicago, IL; Richard Fantus, Brian Helfand, Evanston, IL; Abigail Smith, Ann Arbor, MI; James Griffith, Chicago, IL; Alexander Glaser, Evanston, IL

INTRODUCTION AND OBJECTIVE: The Lower Urinary Tract Dysfunction Research Network (LURN) developed a 10-item symptom index (LURN SI-10) designed for practical clinical use in both men and women for the assessment of lower urinary tract symptoms (LUTS). In this study, we compare the LURN SI-10 with the the widely used American Urological Association Symptom Index (AUA-SI) in men with benign prostatic hyperplasia (BPH)/LUTS to assess validity and determine how frequently the LURN SI-10 identifies symptoms missed by the AUA-SI.

METHODS: LURN SI-10 and AUA-SI questionnaires were prospectively administered to men presenting with BPH/LUTS. Post void dribbling (PVD), bladder pain/discomfort, and urgency urinary incontinence (UUI) were considered present if the patient indicated occurrence of about half the time or more. Responses were tabulated and Pearson correlations between LURN SI-10 and AUA-SI scores were assessed.

RESULTS: The LURN SI-10 and AUA-SI correlate strongly in men with BPH/LUTS (r=0.81; Figure). The bother item of the LURN-10 also correlates strongly with the quality of life (QoL) section of the AUA-SI (r=0.73). The LURN SI-10 identified PVD in 29% (26/91) of patients, bladder pain/discomfort in 13% (12/91) of patients, and UUI in 16% (15/91) of patients.